Home / Innere Medizin / Onkologie / ASCO 2019: Die wichtigsten Take-Home-Messages bei Gastrointestinal-Tumoren
GI-Tumore

ASCO 2019: Die wichtigsten Take-Home-Messages bei Gastrointestinal-Tumoren

Assoz.-Prof. PD Dr. Gerald Prager, Universitätsklinik für Innere Medizin I, MedUni Wien, kommentiert die wichtigsten Daten zu Karzinomen des Magens, der Leber und des Kolons am diesjährigen ASCO.

Interviewpartner:

Redaktion:

Produktion:

Abstracts, die in diesem Video diskutiert werden:

  • Sougklakos I et al. Three versus six months adjuvant FOLFOX or CAPOX for high risk stage II and stage III colon cancer patients: The efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project. Abstract 3500
  • Cremolini C et al. Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC. Abstract 3508
  • Finn RS et al. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). Abstract 4004
  • Tabernero J et al. Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study. Abstract LBA4007
LOGIN

Login

Passwort vergessen?